NASDAQ · ABEO

Abeona Therapeutics Inc.

$6.13 +$0.08 (+1.32%) 1D After hours
Charting by TradingView

Key Metrics

$344.82M
Market cap
5.21×
P/E · TTM
$14.54M
Revenue · TTM
$66.14M
Net income
EPS · TTM $1.33
Dividend yield —
Free cash flow −$85.24M
Beta · 1Y 1.44
EBITDA · TTM $76.64M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 30
    The stock moved +9.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 30
  • May 4
    The stock moved +9.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$344.82M
Enterprise value$194.64M
Shares outstanding57.0M
52-wk range$4.00 – $7.54
Avg volume · 20D484.9K
Net cash $150.18M
Book value / share$2.91
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Abeona Therapeutics Inc.
IPO dateSep 19, 1980
Employees226

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E5.21
P/S23.72
P/FCF—
EV/EBITDA2.54
EV/Sales13.39
Graham №$9.33

Profitability

Gross —
Operating 508.5%
Net 454.9%
FCF -586.2%
ROE / ROIC 70.0% · —

Financial Health

Current ratio5.89
Quick ratio5.70
Debt / equity0.12
Debt / EBITDA 0.24Low leverage
Net cash $150.18M
Working capital$151.94M

Cash Flow · TTM

Operating CF −$77.73M
Capex −$7.51M
Free cash flow −$85.24M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

0.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$9.33 vs $6.13
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings